ClinicalTrials.gg
Sign In

Chronic Urticaria clinical trials

The registry lists 194 studies for Chronic Urticaria across more than 10 countries. 46 are recruiting or about to start. 178 of them are mainly about Chronic Urticaria (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its narrower condition Cryopyrin-Associated Periodic Syndromes too: 229 studies, 49 open.

Get an email when these change. Save the Chronic Urticaria studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
97
Recruiting
24
Terminated
16
Not yet recruiting
16
Active, not recruiting
14
Status unknown
13

Phase

Phase 2
61
Phase 3
47
Phase 1
23
Phase 4
14
Early Phase 1
3

Where

United States
64
Germany
55
China
32
Spain
30
Poland
28
Canada
27

Who runs them

Novartis Pharmaceuticals (37) · Charite University, Berlin, Germany (7) · Genentech, Inc. (6) · Celldex Therapeutics (5) · Hangzhou Highlightll Pharmaceutical Co., Ltd (4) · Sanofi (4) · Allakos Inc. (4) · Organon and Co (3)

What is being tested here

Drugs under test in Chronic Urticaria studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Remibrutinib2912
TLL-018214
UB-221204
Ozureprubart212
Omalizumab11121
Levocetirizine138
Barzolvolimab135
HRS-3095103
PF-06651600102
Apremilast101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 4 open · Antihistamines 1 open · JAK inhibitors 1 open

Coming up

13phase 3 studies under way
20studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 24 Chronic Urticaria studies recruiting now, 11 (46%) set no upper age limit and 9 (38%) stop at 75 or younger. 1 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (21%) take healthy volunteers.

Recruiting studies that take each age, of 24
AgeWomenMen
100 (0%)0 (0%)
1824 (100%)24 (100%)
3023 (96%)23 (96%)
4023 (96%)23 (96%)
5023 (96%)23 (96%)
6523 (96%)23 (96%)
7519 (79%)19 (79%)
8514 (58%)14 (58%)

Across all 194 studies, recruiting or not: 51% stop at 75 or younger and 24% at 65; 20% take children; 0% are for women only and 1% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Chronic Urticaria studies take

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 115 mo8–21 · 15 studies——
Phase 219 mo16–31 · 31 studies——
Phase 324 mo19–32 · 29 studies24 mo19–32 · 27 studies—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

Newly registered2

Studies

Recruiting first, then most recently updated. Showing 50 of 194. Browse all 194 → or search them.